- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
Authors
Keywords
-
Journal
DRUGS
Volume 71, Issue 11, Pages 1441-1467
Publisher
Springer Nature
Online
2011-08-05
DOI
10.2165/11591400-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors
- (2011) Sherwyn L. Schwartz American Journal Geriatric Pharmacotherapy
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
- (2011) Jean Doucet et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
- (2011) Nir Barzilai et al. CURRENT MEDICAL RESEARCH AND OPINION
- Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
- (2011) A. Pfützner et al. DIABETES OBESITY & METABOLISM
- Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
- (2011) M. Nowicki et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects
- (2011) A. Karim et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
- (2010) E M Migoya et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- SIRT1 Takes a Backseat to AMPK in the Regulation of Insulin Sensitivity by Resveratrol
- (2010) M. D. Fullerton et al. DIABETES
- Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
- (2010) B. Ahren et al. DIABETES CARE
- Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
- (2010) D. R. Matthews et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
- (2010) A. J. Scheen DIABETES OBESITY & METABOLISM
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus
- (2010) Masatoshi Kikuchi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes
- (2010) T. Forst et al. DIABETIC MEDICINE
- The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
- (2010) S. Blech et al. DRUG METABOLISM AND DISPOSITION
- Alogliptin
- (2010) Lesley J. Scott DRUGS
- Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
- (2010) Annis Marney et al. HYPERTENSION
- Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome
- (2010) Edwin K. Jackson HYPERTENSION
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
- (2010) B. Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?
- (2010) I. W. Campbell INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
- (2010) S. S. Engel et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2010) Joshua J Neumiller et al. PHARMACOTHERAPY
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
- (2010) Robert Frederich et al. POSTGRADUATE MEDICINE
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Drug evaluation: Vildagliptin-metformin single-tablet combination
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
- (2009) Matthew P. Gilbert et al. AMERICAN JOURNAL OF MEDICINE
- Therapeutic potential for GIP receptor agonists and antagonists
- (2009) Nigel Irwin et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
- (2009) Bo Ahrén BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes
- (2009) Shrikanth H. Havale et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects
- (2009) W. T. CEFALU et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk
- (2009) A. L. PETERS CLEVELAND CLINIC JOURNAL OF MEDICINE
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2009) Richard E. Pratley et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
- (2009) J. Rosenstock et al. CURRENT MEDICAL RESEARCH AND OPINION
- Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes
- (2009) Yan-Ling He et al. CURRENT MEDICAL RESEARCH AND OPINION
- Changing the Treatment Paradigm for Type 2 Diabetes
- (2009) S. Del Prato et al. DIABETES CARE
- Incretin-Based Therapies: Viewpoints on the way to consensus
- (2009) Michael. A. Nauck et al. DIABETES CARE
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2010
- (2009) DIABETES CARE
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
- (2009) G. Bolli et al. DIABETES OBESITY & METABOLISM
- Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
- (2009) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
- (2009) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
- (2009) T. Heise et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
- (2009) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
- (2009) P. Aschner et al. DIABETES OBESITY & METABOLISM
- Diabesity: therapeutic options
- (2009) S. Colagiuri DIABETES OBESITY & METABOLISM
- Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay
- (2009) Kevin Niswender DIABETES OBESITY & METABOLISM
- Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus
- (2009) Masatoshi Kikuchi et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Saxagliptin
- (2009) Sohita Dhillon et al. DRUGS
- Effects of Colesevelam, Rosiglitazone, or Sitagliptin on Glycemic Control and Lipid Profile in Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin Monotherapy
- (2009) Scott Rigby et al. Endocrine Practice
- Vildagliptin in clinical practice: a review of literature
- (2009) Moulinath Banerjee et al. EXPERT OPINION ON PHARMACOTHERAPY
- Exploration of the DPP-4 inhibitors with a focus on saxagliptin
- (2009) Jay H Shubrook et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pharmacotherapy of hyperglycemia
- (2009) Kristen M Kulasa et al. EXPERT OPINION ON PHARMACOTHERAPY
- Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
- (2009) Richard E Pratley EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
- (2009) M. Goodman et al. HORMONE AND METABOLIC RESEARCH
- Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes
- (2009) J. E. Foley et al. HORMONE AND METABOLIC RESEARCH
- Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
- (2009) A. R. Chacra et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
- (2009) Priscilla Hollander et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies
- (2009) Richard E. Pratley et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients
- (2009) Giuseppe Derosa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
- (2009) E.J. Verspohl PHARMACOLOGY & THERAPEUTICS
- Glycaemic control in type 2 diabetes: Targets and new therapies
- (2009) Abd A. Tahrani et al. PHARMACOLOGY & THERAPEUTICS
- Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management
- (2009) Bruce W. Bode POSTGRADUATE MEDICINE
- Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
- (2009) Roger Yazbeck et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Prevalence, Treatment, and Control of Diagnosed Diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004
- (2008) Kwok Leung Ong et al. ANNALS OF EPIDEMIOLOGY
- DPP4 inhibitors for diabetes—What next?
- (2008) Anne-Marie Lambeir et al. BIOCHEMICAL PHARMACOLOGY
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes
- (2008) P COVINGTON et al. CLINICAL THERAPEUTICS
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Medicinal Chemistry Approaches to the Inhibition of Dipeptidyl Peptidase IV
- (2008) Stephen Gwaltney II CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
- (2008) R. A. DeFronzo et al. DIABETES CARE
- Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia*
- (2008) W. A. Scherbaum et al. DIABETES OBESITY & METABOLISM
- Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
- (2008) B. F. Burkey et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*
- (2008) R. Scott et al. DIABETES OBESITY & METABOLISM
- Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*
- (2008) A. J. Garber et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
- (2008) Kenji Nonaka et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The gap between guidelines and practice in the treatment of type 2 diabetes
- (2008) Trond G. Jenssen et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
- (2008) Viswanathan Mohan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
- (2008) C. Pan et al. DIABETIC MEDICINE
- Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
- (2008) H. He et al. DRUG METABOLISM AND DISPOSITION
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers
- (2008) S. Hüttner et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension
- (2008) Goutam C. Mistry et al. JOURNAL OF CLINICAL PHARMACOLOGY
- (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
- (2008) L. Thomas et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia
- (2007) Andrea Mari et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes
- (2007) Koichiro Azuma et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started